Company Overview and News

 
Is Ageas SA (AGESY) Outperforming Other Finance Stocks This Year?

2018-07-10 zacks
Investors focused on the Finance space have likely heard of Ageas SA (AGESY - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
AGS AGESF AGESY

12
Has Ageas SA (AGESY) Outpaced Other Finance Stocks This Year?

2018-06-21 zacks
Investors focused on the Finance space have likely heard of Ageas SA (AGESY - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Finance sector should help us answer this question.
AGS AGESF MS AGESY

 
Ageas SA/NV 2018 Q1 - Results - Earnings Call Slides

2018-05-16 seekingalpha
The following slide deck was published by ageas SA/NV in conjunction with their 2018 Q1 earnings call.
AGS AGESF AGESY

42
Blackstone, Warburg vie for Max Financial stake

2018-05-10 livemint
Mumbai: Global private equity (PE) firms Blackstone Group LP and Warburg Pincus Llc are in separate talks to invest in Max Financial Services Ltd for a minority stake, two people close to the development said.
BGX 500116 500469 IDBI FDBAY FEDA BGLF BX AGESY BGB AGS AGESF FEDS FEDERALBNK

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to EBR:AGS / AGEAS on message board site Silicon Investor.

Gaseous Windbags Gaseous Windbags Gaseous Windbags Tarrant Apparel Group - TAGS Tarrant Apparel Group - TAGS Tarrant Apparel Group - TAGS
Magal Security Systems (MAGS) Magal Security Systems (MAGS) Magal Security Systems (MAGS) MAGS - Magal Security - Airport Bomb Detection + more MAGS - Magal Security - Airport Bomb Detection + more MAGS - Magal Security - Airport Bomb Detection + more
PKS Buyout of BA Six Flags buys Boeing - Thoughts? PKS Buyout of BA Six Flags buys Boeing - Thoughts? PKS Buyout of BA Six Flags buys Boeing - Thoughts? FLGS: Flagstar Bancorp, Inc. FLGS: Flagstar Bancorp, Inc. FLGS: Flagstar Bancorp, Inc.
Software AG Systems (AGS) Software AG Systems (AGS) Software AG Systems (AGS) Flagstar Bank: Amazing growth and Internet banking. Flagstar Bank: Amazing growth and Internet banking. Flagstar Bank: Amazing growth and Internet banking.
Agua Resources Inc. trading Calgary as AGS Agua Resources Inc. trading Calgary as AGS Agua Resources Inc. trading Calgary as AGS ERES - Energy Resources/Cox/Vitsab - Freshtags ERES - Energy Resources/Cox/Vitsab - Freshtags ERES - Energy Resources/Cox/Vitsab - Freshtags